Non-alcoholic fatty liver already affects around 40 percent of the population.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is now the most common chronic liver disease worldwide and affects approximately 30–40% of the adult population. As the disease progresses, MASLD can lead to inflammatory liver disease (steatohepatitis, MASH), liver cirrhosis, and hepatocellular carcinoma.
In Austria, specific drug therapies for advanced stages of the disease are available exclusively within the framework of clinical trials.
For more information about our outpatient clinic for steatotic liver disease (formerly “fatty liver”) as well as about ongoing clinical trials, please visit the following link: